Proven Pathogenic or Probably Pathogenic TBR1 Variant Clinical Trials in Dijon

A Pilot, Multicentre, Controlled, Open-label Study Evaluating 24 Months of Lithium Carbonate Treatment in Patients With TBR1-related Neurocognitive Disorder